

Genomic DNA from Vaccinia Virus, Modified Vaccinia Ankara (MVA)

Catalog No. NR-2634

For research use only. Not for human use.

Contributor:

Linda S. Wyatt, Ph.D. and Bernard Moss, M.D., Ph.D., Chief, Laboratory of Viral Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Manufacturer:

BEI Resources

Product Description:

NR-2634, lot 62153956, genomic DNA was isolated from a preparation of cell lysate and supernatant from chicken embryo fibroblast cells (ATCC® CRL-1590™) infected with vaccinia virus, MVA (BEI Resources NR-1).

NR-2634, lot 5075330, genomic DNA was isolated from a preparation of cell lysate and supernatant from hamster kidney cells (BHK-21; ATCC® CCL-10™) infected with vaccinia virus, MVA (BEI Resources NR-1).

MVA is a highly attenuated strain of vaccinia virus¹ and does not appear to replicate in most mammalian cells. The complete genomic sequence of MVA has been determined (GenBank: U94848).²

NR-2634 has been qualified for PCR applications by amplification of a > 1,000 bp sequence.

Material Provided:

Each vial of NR-2634, lot 62153956 contains 100 µL of viral genomic DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0). The viral genomic DNA is in a background of cellular nucleic acid and carrier RNA. The vial should be centrifuged prior to opening.

Each vial of NR-2634, lot 5075330, which is no longer available, contained a target amount of 1 × 10⁸ copies of viral genomic DNA in TE buffer (pH 7.5) containing sodium azide.

Packaging/Storage:

NR-2634 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH:

Genomic DNA from Vaccinia Virus, Modified Vaccinia Ankara, NR-2634.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- Wyatt, L. S., et al. “Marker Rescue of the Host Range Restriction Defects of Modified Vaccinia Virus Ankara.” Virology 251 (1998): 334-342. PubMed: 9837798.
- Antoine, G., F. Scheiflinger, F. Dörner, and F. G. Falkner. “The Complete Genomic Sequence of the

Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses." *Virology* 244 (1998): 365-396. PubMed: 9601507. GenBank: U94848.

3. Mayr, A., V. Hochstein-Mintzel, and H. Stickl. "Passage History, Properties, and Applicability of the Attenuated Vaccinia Virus Strain MVA." *Infection* 3 (1975): 6-14.

ATCC® is a trademark of the American Type Culture Collection.

